Polyethylene Glycol 3500
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
- Polyethylene Glycol 3500
- Polyethylene Glycol 3500: From Osmotic Laxative (Constipation) to Congenital Ichthyosiform Erythroderma
Polyethylene Glycol 3500: From Osmotic Laxative (Constipation) to Congenital Ichthyosiform Erythroderma
One-Sentence Summary
Polyethylene glycol 3500 (PEG 3500) is a widely used osmotic laxative for constipation. The TxGNN model predicts it may be effective for Congenital Ichthyosiform Erythroderma, but currently no clinical trials and no published literature support this direction — this is a computational prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Osmotic laxative for constipation (based on known pharmacological class; not separately documented in this evidence pack) |
| Predicted New Indication | Congenital Ichthyosiform Erythroderma |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for PEG 3500. Based on known information, it is an oral osmotic laxative whose efficacy in constipation is well established.
The proposed mechanistic link to congenital ichthyosiform erythroderma — a keratinization disorder — rests only on PEG’s hygroscopic (water-attracting) property, which is speculated to soften or hydrate the stratum corneum. This is an indirect analogy, not a validated molecular mechanism connecting systemic PEG administration to keratinocyte differentiation pathways.
The high TxGNN score likely reflects topological similarity within the knowledge graph rather than mechanism-level evidence. No pharmacological, preclinical, or clinical data currently link PEG 3500 to skin keratinization disorders.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
This drug currently has no NDA/marketing authorization records in the evidence pack (market status: Not Marketed, 0 licenses).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is supported only by knowledge-graph topological similarity (L5, Evidence Stage S0) — there are zero clinical trials, zero published literature, and no validated mechanistic pathway connecting PEG 3500 to congenital ichthyosiform erythroderma. The drug is also not currently marketed in the US.
To proceed, the following is needed:
- TFDA/FDA label warnings and contraindications (currently a blocking data gap — required before any safety evaluation can begin)
- Confirmed mechanism of action data for PEG 3500
- Preclinical or mechanistic studies directly linking PEG to keratinization/skin barrier pathways
- Any clinical case reports or exploratory studies to move evidence beyond model-only prediction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.